QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:GNLX

Genelux (GNLX) Stock Price, News & Analysis

$7.30
-0.16 (-2.14%)
(As of 02/29/2024 ET)
Today's Range
$7.08
$7.89
50-Day Range
$6.67
$16.19
52-Week Range
$6.40
$40.98
Volume
107,679 shs
Average Volume
129,846 shs
Market Capitalization
$195.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Genelux MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
379.5% Upside
$35.00 Price Target
Short Interest
Bearish
6.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Genelux in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$556,500 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.10) to ($0.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

693rd out of 958 stocks

Pharmaceutical Preparations Industry

331st out of 448 stocks


GNLX stock logo

About Genelux Stock (NASDAQ:GNLX)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX Stock Price History

GNLX Stock News Headlines

Genelux Stock (NASDAQ:GNLX) Insider Trades
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Genelux VP Sold $191K In Company Stock
Genelux GAAP EPS of -$0.20 misses by $0.02
Genelux Corp GNLX
10% Owner of Genelux Makes $110K Sale
Genelux Insider Trades Send a Signal
VP at Genelux Exercises Options Worth $97K
Genelux 10% Owner Trades Company's Stock
Genelux Recent Insider Activity
See More Headlines
Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/29/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GNLX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$40.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+379.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-5,210,000.00
Pretax Margin
-10,514.71%

Debt

Sales & Book Value

Annual Sales
$11.07 million
Book Value
($1.51) per share

Miscellaneous

Free Float
23,592,000
Market Cap
$195.06 million
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Thomas Zindrick J.D. (Age 65)
    Chairman, CEO & President
    Comp: $500k
  • Mr. Sean Ryder J.D. (Age 55)
    General Counsel & Corporate Secretary
    Comp: $380k
  • Ms. Lourie S. Zak (Age 61)
    CFO & Principal Accounting Officer
  • Dr. Joseph Cappello Ph.D. (Age 67)
    Chief Technical Officer
    Comp: $213.08k
  • Dr. Yong Yu Ph.D. (Age 53)
    Senior Vice President of Clinical Development
    Comp: $242.62k
  • Prof. Paul Scigalla M.D. (Age 78)
    Ph.D., Chief Medical Officer
  • Ms. Caroline Jewett (Age 59)
    VP & Head of Quality














GNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genelux stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings
or view top-rated stocks.

What is Genelux's stock price target for 2024?

4 analysts have issued 1-year price targets for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 379.5% from the stock's current price.
View analysts price targets for GNLX
or view top-rated stocks among Wall Street analysts.

How have GNLX shares performed in 2024?

Genelux's stock was trading at $14.01 at the start of the year. Since then, GNLX stock has decreased by 47.9% and is now trading at $7.30.
View the best growth stocks for 2024 here
.

Are investors shorting Genelux?

Genelux saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 1,220,000 shares, an increase of 9.9% from the January 31st total of 1,110,000 shares. Based on an average daily trading volume, of 132,200 shares, the short-interest ratio is currently 9.2 days. Currently, 6.2% of the shares of the company are sold short.
View Genelux's Short Interest
.

When is Genelux's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our GNLX earnings forecast
.

When did Genelux IPO?

(GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

Who are Genelux's major shareholders?

Genelux's stock is owned by a variety of institutional and retail investors. Top institutional investors include Woodward Diversified Capital LLC (4.05%), Vanguard Group Inc. (3.74%), Northern Trust Corp (0.61%), Provident Wealth Management LLC (0.59%), Charles Schwab Investment Management Inc. (0.56%) and Nuveen Asset Management LLC (0.22%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu.
View institutional ownership trends
.

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNLX) was last updated on 2/29/2024 by MarketBeat.com Staff